• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Purple Innovation Announces Cooperative Framework with Coliseum Capital

    4/13/23 4:05:00 PM ET
    $ADES
    $BIOS
    $LAZY
    $LOGI
    Major Chemicals
    Industrials
    Blank Checks
    Finance
    Get the next $ADES alert in real time by email

    Company to Welcome New Directors to Board

    Adam Gray to Serve as Board Chair

    Gary DiCamillo to Continue to Serve as Lead Independent Director

    Company Will Redeem Cumulative Voting Proportional Representation Preferred Linked Stock

    Purple Innovation, Inc. (NASDAQ:PRPL) ("Purple" or the "Company"), a comfort innovation company known for creating the "World's First No Pressure® Mattress," today announced that it has entered into a binding Memorandum of Understanding to establish a cooperative governance framework (the "Planned Cooperation Agreement") with Coliseum Capital Management, LLC (together with its managed funds and accounts, "Coliseum"), the largest stockholder of the Company owning approximately 44% of its common stock.

    Under the terms of the Planned Cooperation Agreement, which is anticipated to be executed promptly, the Purple Board of Directors (the "Board") will be reconstituted to consist of eight directors. Five of the directors currently serve on the Board: Adam Gray, CEO Robert T. DeMartini, Gary T. DiCamillo, Claudia Hollingsworth and Dawn Zier. The three additional directors who will join were previously nominated by Coliseum in connection with the Company's 2023 annual meeting of stockholders (the "2023 Annual Meeting"): S. Hoby Darling, R. Carter Pate and Erika Serow. Mr. Gray will become Board Chair, while Mr. DiCamillo will continue to serve as Lead Independent Director and will become Chair of the Nomination and Governance Committee.

    Concurrently, Paul Zepf and Pano Anthos will resign as directors of the Company. Scott Peterson, who is a significant stockholder and has served as Board Observer since Purple's September 2022 acquisition of Intellibed, will be a nominee on the Board's slate of directors at the 2023 Annual Meeting in place of Dawn Zier, who previously announced her intention not to stand for reelection. The Company will recommend that stockholders vote in favor of its eight-person Board slate at its 2023 Annual Meeting. Coliseum has committed to vote in favor of the Company's slate of directors.

    Mr. DiCamillo said, "We are pleased to reach this agreement with Coliseum and share its enthusiasm in positioning the Company to fully focus on its business and generating value on behalf of all stakeholders. We also appreciate our longstanding partnership with Adam, the significant contributions he has made and his unwavering support of management." Mr. DiCamillo continued, "Hoby, Carter, Erika and Scott are all highly credentialed, collaborative leaders who together bring significant experience helping to transform and scale companies. We are confident Purple will benefit from their fresh perspectives and skillsets."

    Mr. Gray added, "Throughout his first 16 months as CEO, Rob has demonstrated strong command for the business, inspiring Coliseum to invest meaningfully in support of the transformative vision he has established, the team he is building, and the key strategic and operating priorities he has pursued. I remain energized and excited to work alongside my director colleagues, both incumbent and new, to help Purple navigate its path towards maximizing value for all stockholders. Coliseum has been a supportive investor in Purple for as long as it has been a public company, and we are confident that our continued long-term, constructive engagement will benefit the Company and all of its stockholders."

    Mr. DiCamillo concluded, "On behalf of the entire Board, I would like to thank Paul and Pano for their service as directors of Purple. We are especially grateful for the sage advice and contributions of Paul, who has helped to spearhead the Company through its evolution since entering the public market in 2018. We believe the Company is well positioned to execute on our ‘path to premium' strategy to drive sustainable growth."

    As part of the Planned Cooperation Agreement, Purple will redeem the shares of Proportional Representation Preferred Linked Stock that were previously distributed as a dividend on shares of Purple common stock and terminate its stockholder rights agreement. In addition, the Special Committee of the Board formed in September 2022 will be dissolved. Further, Coliseum will dismiss its litigation against the Company and has agreed to a customary standstill and other terms lasting through the Company's 2024 annual meeting of stockholders, including a commitment not to exceed 44.7% ownership of the Company, subject to certain exceptions. The Memorandum of Understanding and, once it is finalized, the Cooperation Agreement between Purple and Coliseum, will be filed on a Current Report on Form 8-K with the U.S. Securities and Exchange Commission.

    Sidley Austin LLP and Morris, Nichols, Arsht & Tunnell LLP are acting as legal advisors to Purple. Debevoise & Plimpton LLP and Potter Anderson & Corroon LLP are acting as legal advisors to Coliseum.

    About S. Hoby Darling

    Mr. Darling has held several executive roles at Logitech International (NASDAQ:LOGI), including most recently as Head of its Sports and Human Performance business group. He was previously President, Chief Executive Officer and a member of the Board of Directors of Skullcandy (NASDAQ:SKUL), a leading consumer audio and technology company. Prior to joining Skullcandy, Mr. Darling held several senior roles at Nike, Inc. (NYSE:NKE), including as Global General Manager of Nike+ Digital Sport and as Head of Strategy and Planning for Nike Affiliates. Prior to Nike, he served as SVP, Strategic Development and General Counsel, at Volcom, Inc. (NASDAQ:VLCM), a leading manufacturer and marketer of consumer lifestyle products. Mr. Darling began his career as a corporate attorney at the global law firm of Latham & Watkins.

    About R. Carter Pate

    Mr. Pate is a member of the Board of Directors of OptionCare Health (NASDAQ:OPCH) and prior Chairman of the Board of BioScrip, Inc (NASDAQ:BIOS) which merged in 2019 with OptionCare Health. He is also Chairman of the Board of Riverbed Technologies. Previously, he was Chairman of the Board of Red Lion Hotels (NASDAQ:RLH) and a member of the Board of Directors of Advanced Emissions Solutions, Inc. (NASDAQ:ADES). He was the former CEO of ModivCare (NASDAQ:MODV), as well as the former CEO of MV Global Transportation, and for the bulk of his career was the Global Managing Partner of Health Care for PricewaterhouseCoopers among other roles during his career. Mr. Pate was named a NACD Board Leadership Fellow.

    About Erika Serow

    Ms. Serow is the Chief Marketing Officer of Bain & Company ("Bain"), responsible for Bain's global marketing and communication teams, and a member of Bain's Global Operating Council (Executive Leadership Team), where she serves on the Investment and Risk committees. Prior to this role, she was the Global President and US CEO for Sweaty Betty, a premium athletic apparel company. Ms. Serow began her career with a 20-year stint as a consultant at Bain, where she ultimately led the firm's Retail practice in the Americas. She is a member of the Board of Directors of Lazydays Holdings (NASDAQ:LAZY).

    About Scott Peterson

    Mr. Peterson was most recently the Chairman of the Board, Chief Financial Officer and largest investor of Advanced Comfort Technologies, Inc. ("Intellibed"), a luxury mattress company which was acquired by Purple in August 2022. He also was the Chairman of the Board of Utah Capital Investment Corporation, a Utah based venture capital "Fund of Funds" through 2022. Previously, he served on the Board and as Audit Committee Chair for Mattson Technology, Inc. a NASDAQ traded semi-equipment manufacturing company, which was acquired in 2016. He spent the majority of his 32-year audit career with Ernst & Young LLP, the global professional services firm, from which he retired in 2011 as the Pacific Northwest Area Assurance (Audit) Managing Partner, based in the Silicon Valley.

    About Purple

    Purple is a digitally-native vertical brand with a mission to help people feel and live better through innovative comfort solutions. We design and manufacture a variety of innovative, premium, branded comfort products, including mattresses, pillows, cushions, frames, sheets and more. Our products are the result of over 30 years of innovation and investment in proprietary and patented comfort technologies and the development of our own manufacturing processes. Our proprietary gel technology, Hyper-Elastic Polymer®, underpins many of our comfort products and provides a range of benefits that differentiate our offerings from other competitors' products. We market and sell our products through our direct-to-consumer online channels, traditional retail partners, third-party online retailers and our owned retail showrooms. For more information on Purple, visit purple.com.

    Additional Information

    The Company intends to file a definitive proxy statement on Schedule 14A, an accompanying WHITE proxy card and other relevant documents with the U.S. Securities and Exchange Commission (the "SEC") in connection with the solicitation of proxies from the Company's shareholders for the 2023 Annual Meeting. SHAREHOLDERS OF THE COMPANY ARE STRONGLY ENCOURAGED TO READ THE COMPANY'S DEFINITIVE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ALL OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BEFORE MAKING ANY VOTING OR INVESTMENT DECISION BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Shareholders may obtain a copy of the definitive proxy statement, an accompanying WHITE proxy card, any amendments or supplements to the definitive proxy statement and other documents filed by the Company with the SEC at no charge at the SEC's website at www.sec.gov. Copies will also be available at no charge in the "SEC Filings" section of the Company's Investor Relations website at https://investors.purple.com/sec-filings/default.aspx or by contacting the Company's Investor Relations department at [email protected], as soon as reasonably practicable after such materials are electronically filed with, or furnished to, the SEC.

    Participants in the Solicitation

    The Company, its directors and certain of its executive officers are participants in the solicitation of proxies from the Company's shareholders in connection with matters to be considered at the 2023 Annual Meeting. Information regarding the direct and indirect interests, by security holdings or otherwise, of the Company's directors and executive officers is included in the Company's Proxy Statement on Schedule 14A for its 2022 annual meeting of shareholders, filed with the SEC on April 1, 2022, the Company's Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 22, 2023, and in the Company's Current Reports on Form 8-K filed with the SEC from time to time. Changes to the direct or indirect interests of the Company's directors and executive officers are set forth in SEC filings on Initial Statements of Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4. These documents are available free of charge as described above.

    Forward Looking Statements

    Certain statements made in this release that are not historical facts are "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Statements based on historical data are not intended and should not be understood to indicate the Company's expectations regarding future events. Forward-looking statements provide current expectations or forecasts of future events or determinations. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Factors that could influence the realization of forward-looking statements include the risk factors outlined in the "Risk Factors" section of our Annual Report on Form 10-K filed with the SEC on March 22, 2023. Many of these risks and uncertainties have been, and will be, exacerbated by the COVID–19 pandemic and any worsening of the global business and economic environment as a result. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

    No Offer or Solicitation

    This release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities and shall not constitute an offer to sell or a solicitation of an offer to buy any securities nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230413005807/en/

    Get the next $ADES alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADES
    $BIOS
    $LAZY
    $LOGI

    CompanyDatePrice TargetRatingAnalyst
    Logitech International S.A.
    $LOGI
    8/5/2025$109.00Neutral → Outperform
    BNP Paribas Exane
    Nike Inc.
    $NKE
    7/28/2025$93.00Neutral → Overweight
    Analyst
    Nike Inc.
    $NKE
    7/10/2025$76.00Buy → Hold
    DZ Bank
    Nike Inc.
    $NKE
    7/1/2025$85.00Hold → Buy
    Argus
    Nike Inc.
    $NKE
    6/27/2025$66.00 → $78.00Buy
    Needham
    Nike Inc.
    $NKE
    6/27/2025$80.00Hold → Buy
    HSBC Securities
    Nike Inc.
    $NKE
    6/18/2025$75.00 → $66.00Buy
    Needham
    Logitech International S.A.
    $LOGI
    5/7/2025Neutral → Buy
    UBS
    More analyst ratings

    $ADES
    $BIOS
    $LAZY
    $LOGI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Modivcare Enters into Comprehensive Restructuring Agreement to Strengthen its Future, Reduce Debt and Inject Capital

    Supermajority support of secured lenders outlined in Restructuring Support Agreement and via commitment for $100 million in a new investment to support operations and the future growth of the Company Operations and service lines continue uninterrupted, with no expected impact for clients, members, employees or transportation providers Modivcare Inc. (the "Company" or "Modivcare") (NASDAQ:MODV), a technology-enabled healthcare services company providing a platform of integrated supportive care solutions focused on improving health outcomes, today announced that it has taken necessary and decisive action intended to strengthen its financial foundation while continuing to provide access to

    8/20/25 8:18:00 PM ET
    $MODV
    Transportation Services
    Consumer Discretionary

    Option Care Health Announces Chief Financial Officer Transition

    BANNOCKBURN, Ill., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the "Company" or "Option Care Health") (NASDAQ:OPCH), the nation's largest independent provider of home and alternate site infusion services, announced the appointment of Meenal Sethna as Executive Vice President and Chief Financial Officer, effective October 1, 2025. Sethna will succeed Mike Shapiro, who has decided to step down as CFO effective September 30, 2025, following a decade of service to the Company. At the time of the transition, Shapiro will remain with the Company as a Strategic Advisor through at least the first quarter of 2026 to continue to help advance the Company's strategy and ensure a smooth

    8/20/25 8:45:00 AM ET
    $LFUS
    $OPCH
    Electrical Products
    Energy
    Medical/Nursing Services
    Health Care

    Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

    Marks major milestone with completion of enrollment in pivotal Phase 3 NEAT clinical trial evaluating lead asset, eDSP, for the treatment of A-T; topline results expected in first quarter of 2026 Closed financing priced at a premium bringing existing cash position to approximately $35 million; expected to provide runway through Phase 3 topline results and into at least second quarter of 2026 Entered into strategic relationship with Option Care Health to support commercial launch of eDSP in the U.S. Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an

    8/11/25 4:05:00 PM ET
    $OPCH
    $QNCX
    Medical/Nursing Services
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ADES
    $BIOS
    $LAZY
    $LOGI
    SEC Filings

    View All

    ModivCare Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Results of Operations and Financial Condition, Regulation FD Disclosure, Events That Accelerate or Increase a Direct Financial Obligation, Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - ModivCare Inc (0001220754) (Filer)

    8/21/25 6:00:58 AM ET
    $MODV
    Transportation Services
    Consumer Discretionary

    Option Care Health Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Option Care Health, Inc. (0001014739) (Filer)

    8/20/25 4:07:59 PM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    SEC Form SCHEDULE 13G filed by Purple Innovation Inc.

    SCHEDULE 13G - Purple Innovation, Inc. (0001643953) (Subject)

    8/14/25 8:54:30 PM ET
    $PRPL
    Home Furnishings
    Consumer Discretionary

    $ADES
    $BIOS
    $LAZY
    $LOGI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Logitech Int'l SA upgraded by BNP Paribas Exane with a new price target

    BNP Paribas Exane upgraded Logitech Int'l SA from Neutral to Outperform and set a new price target of $109.00

    8/5/25 7:04:41 AM ET
    $LOGI
    Computer peripheral equipment
    Technology

    NIKE upgraded by Analyst with a new price target

    Analyst upgraded NIKE from Neutral to Overweight and set a new price target of $93.00

    7/28/25 8:24:12 AM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    NIKE downgraded by DZ Bank with a new price target

    DZ Bank downgraded NIKE from Buy to Hold and set a new price target of $76.00

    7/10/25 8:36:12 AM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    $ADES
    $BIOS
    $LAZY
    $LOGI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Pate R Carter bought $20,391 worth of shares (750 units at $27.19), increasing direct ownership by 2% to 41,910 units (SEC Form 4)

    4 - Option Care Health, Inc. (0001014739) (Issuer)

    8/21/25 6:26:07 PM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    Director Kraemer Harry M Jansen Jr bought $977,278 worth of shares (36,000 units at $27.15), increasing direct ownership by 11% to 375,390 units (SEC Form 4)

    4 - Option Care Health, Inc. (0001014739) (Issuer)

    8/21/25 6:25:33 PM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    Director Sullivan Timothy P bought $550,200 worth of shares (20,000 units at $27.51), increasing direct ownership by 68% to 49,229 units (SEC Form 4)

    4 - Option Care Health, Inc. (0001014739) (Issuer)

    8/21/25 6:24:54 PM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    $ADES
    $BIOS
    $LAZY
    $LOGI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Pate R Carter bought $20,391 worth of shares (750 units at $27.19), increasing direct ownership by 2% to 41,910 units (SEC Form 4)

    4 - Option Care Health, Inc. (0001014739) (Issuer)

    8/21/25 6:26:07 PM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    Director Kraemer Harry M Jansen Jr bought $977,278 worth of shares (36,000 units at $27.15), increasing direct ownership by 11% to 375,390 units (SEC Form 4)

    4 - Option Care Health, Inc. (0001014739) (Issuer)

    8/21/25 6:25:33 PM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    Director Sullivan Timothy P bought $550,200 worth of shares (20,000 units at $27.51), increasing direct ownership by 68% to 49,229 units (SEC Form 4)

    4 - Option Care Health, Inc. (0001014739) (Issuer)

    8/21/25 6:24:54 PM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    $ADES
    $BIOS
    $LAZY
    $LOGI
    Leadership Updates

    Live Leadership Updates

    View All

    Option Care Health Announces Chief Financial Officer Transition

    BANNOCKBURN, Ill., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the "Company" or "Option Care Health") (NASDAQ:OPCH), the nation's largest independent provider of home and alternate site infusion services, announced the appointment of Meenal Sethna as Executive Vice President and Chief Financial Officer, effective October 1, 2025. Sethna will succeed Mike Shapiro, who has decided to step down as CFO effective September 30, 2025, following a decade of service to the Company. At the time of the transition, Shapiro will remain with the Company as a Strategic Advisor through at least the first quarter of 2026 to continue to help advance the Company's strategy and ensure a smooth

    8/20/25 8:45:00 AM ET
    $LFUS
    $OPCH
    Electrical Products
    Energy
    Medical/Nursing Services
    Health Care

    Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

    Marks major milestone with completion of enrollment in pivotal Phase 3 NEAT clinical trial evaluating lead asset, eDSP, for the treatment of A-T; topline results expected in first quarter of 2026 Closed financing priced at a premium bringing existing cash position to approximately $35 million; expected to provide runway through Phase 3 topline results and into at least second quarter of 2026 Entered into strategic relationship with Option Care Health to support commercial launch of eDSP in the U.S. Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an

    8/11/25 4:05:00 PM ET
    $OPCH
    $QNCX
    Medical/Nursing Services
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Jørgen Vig Knudstorp Nominated to Join NIKE, Inc. Board of Directors

    NIKE, Inc. (NYSE:NKE) today announced Jørgen Vig Knudstorp has been nominated for election to its Board of Directors at the Company's 2025 annual meeting of shareholders, to be held on September 9, 2025. Mr. Knudstorp was President and Chief Executive Officer of the LEGO Group ("LEGO") from 2004 to 2016, Executive Chair of LEGO Brand Group from 2017 to 2023 and currently serves as Deputy Chair of the LEGO Foundation. He previously held various leadership positions at LEGO from 2001 to 2004. "Jørgen's strong global experience with brand and digital marketing, strategy, and consumer products, as well as his development and fostering of culture and values, will make him an excellent additi

    6/24/25 4:15:00 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    $ADES
    $BIOS
    $LAZY
    $LOGI
    Financials

    Live finance-specific insights

    View All

    NIKE, Inc. Declares $0.40 Quarterly Dividend

    NIKE, Inc. (NYSE:NKE) announced today that its Board of Directors has declared a quarterly cash dividend of $0.40 per share on the Company's outstanding Class A and Class B Common Stock payable on October 1, 2025, to shareholders of record at the close of business on September 2, 2025. About NIKE, Inc. NIKE, Inc., headquartered near Beaverton, Oregon, is the world's leading designer, marketer and distributor of authentic athletic footwear, apparel, equipment and accessories for a wide variety of sports and fitness activities. Converse, a wholly-owned NIKE, Inc. subsidiary brand, designs, markets and distributes athletic lifestyle footwear, apparel and accessories. For more information,

    8/7/25 4:15:00 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    Option Care Health Announces Financial Results for the Second Quarter Ended June 30, 2025

    BANNOCKBURN, Ill., July 30, 2025 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the "Company" or "Option Care Health") (NASDAQ:OPCH), the nation's largest independent provider of home and alternate site infusion services, announced today financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights Net revenue of $1,416.1 million, up 15.4% compared to $1,227.2 million in the second quarter of 2024Gross profit of $269.0 million, or 19.0% of net revenue, up 7.9% compared to $249.4 million, or 20.3% of net revenue, in the second quarter of 2024Net income of $50.5 million, compared to net income of $53.0 million, in the second quarter of 20

    7/30/25 7:00:00 AM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    Purple Innovation Reports Second Quarter 2025 Results; Reaffirms 2025 Guidance

    Net Loss Exceeded Expectations; Adjusted EBITDA Margin Improved 120 Basis Points versus Last Year Strong Rejuvenate 2.0 Demand More than Double the Rejuvenate 1.0 Launch in DTC Mattress Firm Rollout Progressing on Schedule  LEHI, Utah, July 29, 2025 /PRNewswire/ -- Purple Innovation, Inc. (NASDAQ:PRPL) ("Purple"), a comfort innovation company whose mattresses promise to give you "less pain, better sleep," today announced results for the second quarter ended June 30, 2025. "We are pleased with our second quarter performance, which reflects our disciplined execution and continue

    7/29/25 4:05:00 PM ET
    $PRPL
    Home Furnishings
    Consumer Discretionary

    $ADES
    $BIOS
    $LAZY
    $LOGI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by ModivCare Inc.

    SC 13D/A - ModivCare Inc (0001220754) (Subject)

    12/13/24 9:05:42 PM ET
    $MODV
    Transportation Services
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by ModivCare Inc.

    SC 13D/A - ModivCare Inc (0001220754) (Subject)

    12/13/24 5:07:48 PM ET
    $MODV
    Transportation Services
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by ModivCare Inc.

    SC 13D/A - ModivCare Inc (0001220754) (Subject)

    12/9/24 7:46:13 PM ET
    $MODV
    Transportation Services
    Consumer Discretionary